ArticleFrontiers in oncology2026
Interpretable prediction of Ki-67 expression in breast cancer through integrated photoacoustic radiomics and clinical parameters.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to develop a noninvasive method for preoperatively predicting Ki-67 expression in breast cancer (BC) by integrating radiomics features derived from photoacoustic/ultrasound (PA/US) imaging with clinical factors. Materials and methods: A total of 223 patients with pathologically confirmed BC underwent PA/US imaging before surgery. Radiomics features were extracted from tumor regions, standardized, and selected using statistical testing, correlation analysis, and least absolute shrinkage and selection operator (LASSO) regression. Ten machine learning algorithms were compared, and the best-performing classifier was used to construct the radiomics model. Clinical variables significantly associated with Ki-67 expression were then incorporated to build a combined model. Model performance was evaluated using receiver operating characteristic (ROC) curve analysis, calibration analysis, and decision curve analysis. Results: In the test set, the clinical, radiomics, and combined models achieved areas under the ROC curve (AUCs) of 0.722, 0.826, and 0.849, respectively. The combined model also demonstrated higher sensitivity (0.957) and negative predictive value (0.867), indicating strong capability in identifying patients with high Ki-67 expression. SHAP analysis confirmed that texture- and intensity-related imaging features played important roles in model prediction. Conclusion: PA/US-based radiomics provides a quantitative, interpretable, and clinically valuable approach for assessing tumor proliferation in BC. The combined model exhibited superior accuracy over single-modality models and shows promise as an effective supplementary tool for individualized preoperative evaluation of Ki-67 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.